CRISPR Cas9 Gene Editing - CRISPR Library Screening - Gene Knockout Cell Line - Knock in Cell Line - Cas12a

Gene Editing Service

  Knockout Cell Line

  Point Mutation Cell Line

  Knock-In Cell Line

  Overexpression Cell Line

  iPSC Gene Editing
Gene Delivery Service

  Vector Construction

●  Knockout Vector Construction ●  Point Mutation Vector Construction ●  Knock-In Vector Construction ●  Overexpression Vector Construction

  Lentiviral Packaging

  RNP Delivery

  Electroporation
CRISPR Detection Service

crRNA Design & Synthesis

CRISPR Detection Service
CRISPR Library Screening

CRISPR Library Screening

CRISPR-scRNA-seq integration
Supporting Services

Monoclonal Screening

Customized Enzyme
Collaboration Services

Mouse Model Solutions

Mouse Model Solutions

服务优势

Strong Alliance, Defining New Standards in Gene Editing

详情描述
Review

Expanding Our Reach: From Human Cells to Animal Models

To better serve the evolving needs of our clients, EDITGENE now offers extended gene editing serv ices beyond human cells through a trusted partnership with an experienced mouse model CRO.

★ Collaboration Highlight:

While EDITGENE specializes in CRISPR-based gene editing in human cells, our strategic collaborati on with a leading mouse model provider allows us to support clients with both in vitro and in vivo ge ne editing solutions—all under one coordinated service experience.

★ What This Means for You:

-Access to genetically engineered mouse models (e.g., KO, KI, conditional, humanized)

-Simplified project coordination across human and animal systems

-One-stop solution from cell-based validation to in vivo functional studies

★ How we streamline and expedite your research progress?

Our collaboration allows clients to:

Translate discoveries from human cell models to animal models efficiently

Eliminate the need to manage multiple vendors

Ensure continuity and scientific consistency across platforms

From Lab to Industry: Scalable Mouse Model Solutions

In the traditional approach, the preparation of mouse models takes 6–8 months or even years. The prolonged process of animal modeling significantly hinders the progress and efficiency of new drug development and disease research. A new generation of animal model technology—combining tetraploid complementation techniques with precise gene-editing and mouse embryonic stem cell technologies—enables editing at virtually any target gene locus.

Building on this foundation, TurboMice™ has established and refined an engineering system for tetraploid complementation technology, increasing the birth rate of mice prepared using this approach from the previously reported 1–5% to 30–60%. This breakthrough overcomes the technical bottleneck that has limited the large-scale industrial application of tetraploid complementation. TurboMice™ is the first company in the world to achieve the transition of tetraploid complementation technology from laboratory research to industrial application, and it is poised to have a transformative impact on new drug development and basic medical research.

Featured Services & Products

Service Advantages

a. Ultra-fast process

TurboMice™ technology shortens the modeling cycle to just 2 months. The first-generation mice are 100% homozygous, enabling quick delivery of homozygous mice without additional breeding.

The ability to rapidly obtain large numbers of precisely gene-edited homozygous mice can significantly accelerate drug development pipelines,reduce efficacy evaluation risks in clinical trials, and lower costs. TurboMice™ technology allows pharmaceutical companies to obtain 3–20 homozygous mice for preliminary testing within 2–4 months. Based on customer validationresults, it is possible to adjust the editing strategy, with new strategies completing model iterations and upgrades within another 2–4 months. This multi-pronged, personalized approach can save substantial development time, reduce potential research risks, and strengthen the early-mover advantage in drug development.

b. Multiple Sites

TurboMice™ technology offers unparalleled flexibility in selecting the location, length, and number of genetic modification sites, without the complications of allele segregation. It is the optimal choice on the market today for constructing multi-locus combined phenotype models.

The technology allows simultaneous editing of more than three genes and loci, eliminating the need for a breeding process. By editing stem cells directly, we can produce homozygous mouse models with multiple gene-editing sites. These complex, high-value models provide the innovative tools needed for cutting-edge drug research.

c. Long Fragments

TurboMice™ technology enables precise gene editing for fragments longer than 20kb, facilitating the rapid development of complex models such as humanized, conditional knockout (CKO), and large fragment knock-in (KI) mice.

d. High Consistency

TurboMice™ complementation technology produces model mice with excellent genetic consistency and minimal individual variation, greatly improving the accuracy of efficacy assessments.

F0 generation gene-engineered mice created using traditional methods are often chimeric, with each individual in the same batch possessing different genetic material. Subsequent breeding typically involves selecting one individual for expansion, and only after several generations of breeding can stable and genetically consistent mice be obtained. In contrast, F0 generation mice produced by TurboMice™ technology are the desired model mice from the start. Each batch of gene-engineered mice originates from a single cell, resulting in nearly identical genetic material. This reduces experimental errors caused by genetic variability and ensures more reliable data for efficacy evaluation and other experimental studies.

e. Greater Precision

TurboMice™ technology enables in situ precise gene editing at the stem cell level, ensuring strong tissue specificity. The resulting mouse models are better suited to meet the needs of new drug development.

In contrast, traditional methods for creating transgenic humanized ACE2 mice rely on random insertion of the K18-ACE2 promoter. This approach lacks precision, and the humanized ACE2 in the resulting models does not exhibit tissue specificity. Our humanized ACE2 mouse models, on the other hand, achieve tissue-specific expression across different organs (Figures C and D), better replicating clinical manifestations.

f. High Expression

Humanized mouse models often exhibit low expression levels of the target gene, making them unsuitable for subsequent experimental needs. Our proprietary Enhancer-Plus analysis platform helps clients achieve higher expression levels of humanized genes.

After completing the world’s first batch production of ACE2 humanized mice in just 35 days, we have performed four rounds of iterative upgrades on the ACE2 humanized mouse model using Enhancer optimization and codon optimization. As a result, the expression levels of humanized ACE2 have steadily increased and now approach endogenous expression levels.

Customizable Mouse Models

We offer a wide range of customizable mouse models. Based on the chosen construction method, we provide various gene-editing services, including gene knockout, point mutation, humanization, and more.